^
    Back
    Association details:
    Biomarker:MYD88 L265P
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Yinuokai (orelabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patients

    Published date:
    11/04/2021
    Excerpt:
    ICP-CL-00105 is a single arm, multiple centers, open label, phase 2 study in clinical and histopathological confirmed patients with R/R WM requiring treatment per IWWM-7. The MRR was higher in patients with MYD88L265P…
    DOI:
    10.1182/blood-2021-149350